US 11,654,213 B2
Implantable scaffolds for treatment of sinusitis and method of reducing inflammation
Changcheng You, Northbridge, MA (US); Quynh Pham, Methuen, MA (US); and Danny Concagh, Medfield, MA (US)
Assigned to LYRA THERAPEUTICS, INC., Watertown, MA (US)
Filed by LYRA THERAPEUTICS, INC., Watertown, MA (US)
Filed on Apr. 3, 2020, as Appl. No. 16/839,832.
Application 16/839,832 is a continuation of application No. 16/180,413, filed on Nov. 5, 2018, granted, now 10,864,298.
Application 16/180,413 is a continuation of application No. 15/492,103, filed on Apr. 20, 2017, granted, now 10,232,082, issued on Mar. 19, 2019.
Application 15/492,103 is a continuation in part of application No. 15/197,686, filed on Jun. 29, 2016, granted, now 10,219,894, issued on Mar. 5, 2019.
Claims priority of provisional application 62/186,030, filed on Jun. 29, 2015.
Claims priority of provisional application 62/289,982, filed on Feb. 2, 2016.
Claims priority of provisional application 62/332,134, filed on May 5, 2016.
Prior Publication US 2020/0316253 A1, Oct. 8, 2020
Int. Cl. A61L 27/34 (2006.01); A61F 2/18 (2006.01); A61M 25/10 (2013.01); A61M 31/00 (2006.01); A61L 27/54 (2006.01); A61K 31/58 (2006.01); A61L 27/58 (2006.01); A61L 27/18 (2006.01); A61L 27/56 (2006.01); A61F 2/90 (2013.01)
CPC A61L 27/34 (2013.01) [A61F 2/186 (2013.01); A61F 2/90 (2013.01); A61K 31/58 (2013.01); A61L 27/18 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); A61L 27/58 (2013.01); A61M 25/10 (2013.01); A61M 31/002 (2013.01); A61F 2210/0004 (2013.01); A61F 2250/0031 (2013.01); A61F 2250/0067 (2013.01); A61L 2300/222 (2013.01); A61L 2300/41 (2013.01); A61L 2300/604 (2013.01); A61L 2300/608 (2013.01); A61M 2025/105 (2013.01); A61M 2210/0681 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for reducing inflammation of the nasal tissue caused by a sinus condition in an individual in need of treatment, said method comprising delivering an expandable implant to the sinus cavity where the implant self-expands and is in apposition with the walls of the sinus cavity, wherein the implant comprises a plurality of strands, said strands comprising a conformal coating comprising an anti-inflammatory agent in an amount effective to reduce inflammation, and a conformal topcoat layer, which is disposed over the conformal coating wherein release of the anti-inflammatory agent from the implant is continuous for a period of at least 12 weeks after delivery to the sinus cavity such that inflammation is reduced, wherein the thickness of the topcoat layer causes the anti-inflammatory agent to be released in a more linear fashion.